Rheumatologic complications of checkpoint inhibitor immunotherapy: a review

Abstract

Background: Immune Checkpoint Inhibitors (ICIs) are currently used in the management of various cancers. However, they tend to cause adverse effects, collectively known as immune related adverse effects, (irAEs)by causing
tissue damage due to immune activation.
Objective: The aim of this literature review is to address those rheumatological irAEs associated with the use of ICIs and how to manage them.
Data source: The literature review uses medical science-based literature published locally and internationally on the risk of rheumatological immune related adverse effects.
Conclusion: A spectrum of rheumatological irAEs have been linked to the treatment of various malignancies with ICIs, the most common being inflammatory arthritis. Most rheumatological irAEs can be managed successfully by use of glucocorticoids